1	Identification of Novel Syncytiotrophoblast Membrane Extracellular Vesicles Derived
2	Protein Biomarkers in Early-onset Preeclampsia: A Cross-Sectional Study.
3	Toluwalase Awoyemi DPhil ^{1*} , Shuhan Jiang MB;BS ¹ , Bríet Bjarkadóttir DPhil ¹ , Ms. Maryam
4	Rahbar MSc ¹ , Prasanna Logenthiran MB;BS ¹ , Gavin Collett PhD ¹ , Wei Zhang PhD ¹ , Adam
5	Cribbs PhD ² , Ana Sofia Cerdeira PhD ¹ & Manu Vatish DPhil ¹
6	
7	
8	1 Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford,
9	United Kingdom
10	2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
11	University of Oxford, Oxford, United Kingdom
12	
13	
14	
15	
16	
17	
18	
10	*Corresponding outhors Dr Many Vatish MPPCh PA (Hone) DPhil MA EMPCOC
19	"Corresponding author: Di Manu Valish, MBBCh, BA (Holis), Drini, MA, FMRCOG
20	Manu.vatish@wrh.ox.ac.uk, Phone number- +441865221009, Fax number-01865769141
21	Address: Nuffield Department of Women's and Reproductive Health, University of Oxford,
22	Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
23	Abstract

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Background: Preeclampsia (PE), a multi-systemic hypertensive pregnancy disease that affects
2-8% of pregnancies worldwide, is a leading cause of adverse maternal and fetal outcomes.
Current clinical PE tests have a low positive predictive value for PE prediction and diagnosis.
The placenta notably releases extracellular vesicles from the syncytiotrophoblast (STB-EV)
into the maternal circulation.

Objective: To identify a difference in placenta and STB-EV proteome between PE and normal
pregnancy (NP), which could lead to identifying potential biomarkers and mechanistic insights.
Methods: Using ex-vivo dual lobe perfusion, we performed mass spectrometry on placental
tissue, medium/large and small STB-EVs isolated from PE (n = 6) and NP (n = 6) placentae.
Bioinformatically, mass spectrometry was used to identify differentially carried proteins.
Western blot was used to validate the identified biomarkers. We finished our investigation with
an in-silico prediction of STB-EV mechanistic pathways.

Results: We identified a difference in the STB-EVs proteome between PE and NP. Filamin B,
collagen 17A1, pappalysin-A2, and scavenger Receptor Class B Type 1) were discovered and
verified to have different abundances in PE compared to NP. In silico mechanistic prediction
revealed novel mechanistic processes (such as abnormal protein metabolism) that may
contribute to the clinical and pathological manifestations of PE.

41 Conclusions: We identified potentially mechanistic pathways and identified differentially
42 carried proteins that may be important in the pathophysiology of PE and are worth investigating
43 because they could be used in future studies of disease mechanisms and as biomarkers.

44 **Funding:** This research was funded by the Medical Research Council (MRC Programme Grant

45 (MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)

46 Keywords: Syncytiotrophoblast membrane extracellular vesicles (STB-EVs), Preeclampsia,

47 Biomarkers, Proteomics, Placenta EVs, mechanisms

48 Introduction

Preeclampsia (PE) is a significant cause of maternal and neonatal morbidity and mortality. 49 affecting 2-8% of all pregnancies(Lisonkova & Joseph, 2013). 50 It is characterized by 51 hypertension (systolic blood pressure > 140mmHg / diastolic pressure > 90mmHg), and either 52 proteinuria (protein/creatinine ratio of \geq 30 mg/mmol or more), or evidence of maternal acute kidney injury, liver dysfunction, neurological abnormalities, hemolysis, or thrombocytopenia, 53 and/or fetal growth restriction.("ACOG Practice Bulletin No. 202: Gestational Hypertension 54 55 and Preeclampsia," 2019; Brown et al., 2018) Predicting or early detection of PE is thus of 56 extreme importance to reduce the chance of long term complications but this has been 57 challenging due to the limitations of current predictive models and biochemical tests (which lack in positive predictive value)(Zeisler et al., 2016). The existing tests perform far better in 58 59 ruling out rather than ruling in PE. They are also most effective shortly before the onset of the 60 disease and within a specific time frame (1 or 2 weeks) rather than earlier in pregnancy(Thadhani et al., 2022). 61

62 The pathophysiology of PE implicates the placenta. It is known that PE can occur in trophoblastic tumors (without the presence of a fetus); that PE is more common in multiple 63 pregnancy (with greater placental mass) and that it has occurred in ectopic pregnancies 64 (excluding the involvement of the uterus)(Billieux et al., 2004; Hailu et al., 2017; C. W. G. 65 66 Redman et al., 2022; Soto-Wright et al., 1995). Finally, delivery of the placenta (irrespective 67 of gestational age) is currently the only cure for the condition(C. Redman, 2014).

The placental syncytiotrophoblast (STB) layer, the interface between the fetus and the mother 68 69 which lies in direct contact with the maternal circulation. EVs, including STB-EVs, are 70 membrane-bound and cell-derived particles that carry different cargos, including proteins, ribonucleic acid (RNA), deoxyribonucleic acid (DNA) and lipids(Raposo & Stoorvogel, 2013). 71 72 EVs are based on size into medium/large STB-EVs (MVs, 201-1000nm) or small STB-EVs

(≤200nm)(Dragovic et al., 2015a). The release of syncytiotrophoblast extracellular vesicles 73 (STB-EVs), including both size ranges, into the maternal circulation increases with gestation 74 and is further elevated in PE (Germain et al., 2007; Goswamia et al., 2006). Variations in cargo 75 content are evident among different subsets of syncytiotrophoblast-derived extracellular 76 77 vesicles (STB-EVs), with medium/large STB-EVs (m/ISTB-EVs) showing higher levels of total RNA and total protein in comparison to small STB-EVs (sSTB-EVs)(Zabel et al., 2021). 78 Additionally, distinct miRNA profiles have been noted to differ in abundance between these 79 80 subsets. While limited studies have investigated disparities in EV subtypes, Keerthikumar et al reported that exosomes and other small extracellular vesicles (EVs) have a more pronounced 81 impact on cell migration and proliferation than the larger EVs known as ectosomes 82 83 (Keerthikumar et al., 2015). Furthermore, Minciacchi et al demonstrated that large EVs exhibit greater efficiency in reprogramming fibroblasts and promoting the formation of endothelial 84 85 cell tubes when compared to small EVs(Minciacchi et al., 2017).

86

In addition, when it comes to immune cell-derived EVs, large EVs were found to induce the 87 88 secretion of Th2-associated cytokines, while both medium and small EVs (pelleted at 10,000g 89 and 100,000g) triggered the release of Th1 cytokines(Tkach et al., 2017). These functional distinctions were also observed in STB-EVs. Specifically, our investigation unveiled that 90 91 normal pregnancy (NP) medium/large-sized STB-EVs significantly enhanced the transcriptional expression of pro-inflammatory cytokines in contrast to pathological (PE) 92 medium/large-sized STB-EVs(Awoyemi et al., 2021). However, there was no significant 93 difference in the small STB-EV population between the two groups, although, in general, NP 94 95 small STB-EVs exhibited a slight upregulation of the same cytokines(Awoyemi et al., 2021). It is reasonable to conduct further in-depth exploration into the qualitative functional properties 96 97 of distinct STB-EVs, with the initial step being a comprehensive characterization of these

98 diverse subtypes. The presence of proteins, RNA species and DNA in EVs combined with their 99 constitutional release as inter-cellular signaling moieties means they also have potential in disease prediction and diagnosis. Notably, these distinct STB-EV subtypes have also been 100 101 identified in the bloodstream. Nakahara et al extensive review compiles a collection of studies 102 that have specifically isolated various subtypes of EVs from maternal plasma(Nakahara et al., 2020). In this study, we performed proteomic analysis of placenta and STB-EVs in PE and NP 103 104 to identify potential placenta-derived biomarkers. We also conducted in silico analysis on the 105 proteomes to detect potential molecular targets, mechanisms, and processes of PE.

106

Methods 107

Ethics approval and patient information 108

109 Oxfordshire Research Ethics Committee C (07/H0606/148) approved this study. Normal pregnancy was a healthy singleton pregnancy with normal maternal blood pressure. PE was 110 defined as new (after 20 weeks) systolic blood pressure 140 mmHg or diastolic pressure 90 111 112 mmHg, proteinuria (protein/creatinine ratio of 30 mg/mmol or more). None of our patients had maternal acute kidney injury, liver dysfunction, neurological features, haemolysis, 113 thrombocytopenia, and/or foetal growth restriction. This study included only early-onset PE 114 patients (diagnosed before 34 weeks gestation). After informed consent, placenta was obtained 115 from women undergoing elective caesarian section without labor were collected. 116

117

Placenta sample preparation and syncytiotrophoblast membrane extracellular vesicles 118 (STB-EVs) enrichment. 119

120 Placenta biopsies were obtained adjacent to the perfused lobe and immediately frozen at -80°C pending transfer to the Target Discovery Institute (Oxford) for proteomic analysis. We 121 122 obtained STB-EVs via placental perfusion as previously described (Dragovic et al., 2015b). Our

123 STB-EV enrichment and categorization process has been deposited on EV Track 124 ([http://www.EVTRACK.org], EV-TRACK ID: EV 220157) with a score of 78% (the average score on EV track for 2021 is 52 %). Full details can be found in the supplemental 125 126 data.

127

Characterization of syncytiotrophoblast membrane extracellular vesicles (STB-EVs) 128

Enriched STB-EVs were resuspended in filtered phosphate buffered saline (fPBS) and 129 characterized with bicinchoninic acid (BCA) assay (for protein concentration) and nanoparticle 130 131 tracking analysis (NTA) (for particle number and size profile). We also phenotyped the STB-EVs with transmission electron microscopy (for morphology), flow cytometry (BD 132 Biosciences, LSRII), and western blot (for immunophenotyping). Flow cytometric analysis 133 134 was performed using antibodies to placental alkaline phosphatase - PLAP- (to confirm 135 syncytiotrophoblast origin), CD 41 (to identify co-isolated platelet EVs, CD235 a/b (to identify 136 co-isolated red blood cell EVs), HLA class I and II (to identify co-isolated white blood cell 137 EVs). Western blot was probed for placental alkaline phosphatase (PLAP [1.667 mg/ml] at 1:1000 dilution in house antibody), the known EV markers CD 63 ([200ug/ml] at 1:1000 138 dilution, Sc-59286, Santa Cruz Biotechnology), ALIX ([200ug/ml] at 1:1000 dilution, Sc-139 53538, Santa Cruz Biotechnology) and the known negative EV marker Cytochrome C 140 141 ([200ug/ml] at 1:1000 dilution, Sc-13156, Santa Cruz Biotechnology) as recommended by the 142 international society for extracellular vesicles (ISEV) and subsequently incubated with the 143 corresponding secondary antibody anti-mouse, anti-rabbit polyclonal or goat immunoglobulins/HRP (at 1: 2000 dilution, Dako UK Ltd, Cambridgeshire UK). Details of 144 145 nanoparticle tracking analysis and transmission electron microscopy can be found in the supplemental data. 146

medRxiv preprint doi: https://doi.org/10.1101/2023.06.03.23290935; this version posted November 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Sample preparation for Mass Spectrometric analysis and bioinformatic analysis of proteomic data from placenta tissue, medium/large, and small STB-EVs

STB-EVs and placental tissue samples were processed for liquid chromatography mass 150 151 spectrometry (LC-MS) (Target Discovery Institute, Oxford). Briefly, STB-EVs and placental tissue samples (10 µg total protein) were reduced with dithiothreitol (DTT) (final concentration 152 5 mM) for 60 min at room temperature, then alkylated with iodoacetamide (final concentration 153 154 20 mM) for 60 min at room temperature. After precipitation with methanol/chloroform, the 155 protein pellet was resuspended in 6 M urea, and then the urea concentration was reduced to < 156 1 M with milliQ H2O. Trypsin was added to achieve the final trypsin: protein ratio of 1:50, 157 and the samples were digested overnight at 37°C. According to the manufacturer's instructions, peptides were purified on Waters C18 Sep-Pak cartridges. The purified peptides were dried 158 159 down in a speed vac, resuspended in 2% acetonitrile/0.1% trifluoroacetic acid, and diluted 1:20 160 before injection. Peptides were injected into an LC-MS system comprised of a Dionex ultimate 3000 Nano LC (Liquid Chromatography) and a Thermo Q-Exactive mass spectrometer. 161 162 Peptides were separated on a 50-cm-long EasySpray column (ES803; Thermo Fisher) with a 75 µm inner diameter and a 60-minute gradient of 2% to 35% acetonitrile in 0.1% formic acid 163 and 5% dimethyl sulfoxide (DMSO) at a flow rate of 250 nl/min. The Top 15 most abundant 164 peaks were fragmented after isolation with a mass window of 1.6 and a resolution of 17,500. 165 166 The normalized collision energy was 28% (higher collisional dissociation). Raw data was 167 imported and analyzed with Progenesis QI (Waters) using standard settings and manually refined retention time alignment. MS/MS data was searched in Mascot (Matrix Science) 168 against a human database (fused Uniprot/Trembl, 03/2018), with oxidation (Met), deamidation 169 170 (Gln/Asn) and carbamidomethylation (Cys) fixed as variable modifications. Precursor mass tolerance was set to 10 parts-per-million (ppm) and fragment tolerance to 0.04 Da. Peptide 171

Page **| 8**

identifications were FDR (False Discovery Rate) adjusted at 1%, and identifications with
Mascot score < 20 were discarded.

174

175 Raw label-free quantitation (LFO) data was imported and analyzed in Perseus (Max Planck 176 Institute of Biochemistry). Differential expression was performed by conducting a two-sample independent Student t-test. Multiple testing was corrected via permutation-based FDR (False 177 178 Discovery Rate) with the default software settings. Proteins were considered differentially 179 expressed if their false discovery rate (FDR) was less than 0.05 and their fold change was 180 greater than or equal to 1 or less than or equal to -1. G: Profiler (https://biit.cs.ut.ee/gprofiler/gost) was used for functional enrichment analysis of the 181 differentially expressed proteins (DEPs). The enriched pathways/terms from the KEGG 182 183 database and Gene ontology database, gene ontology biological process (GO: BP), gene 184 ontology molecular function (GO: MF), and gene ontology clinical component (GO: CC) were ascertained for each set of DEPs by applying hypergeometric testing. Multiple testing was 185 186 corrected by Benjamin Hochberg correction, and the significance level was set to < 0.05. The 187 mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD031953.132 188

189

Bioinformatic analysis of proteomic data from placenta tissue, medium/large and small STB-EVs

Persus (Max Planck Institute of Biochemistry) was used for the analysis, along with the accompanying documentation and tutorials. To remove invalid data, we pre-processed the raw data by log transforming and filtering. Missing values were imputed at random from a normal distribution using the following parameters: width = 0.3 and downshift = 1.8. To ensure conformity to the normal distribution, the underlying distribution was visually inspected with a histogram before and after missing data imputation. The data was then transformed furtherby deducting each (transformed) value from the highest occurring protein expression value.

Principal component analysis (PCA), heatmaps, and Pearson correlation matrices were used to
further investigate the data. The data was analyzed using the correlation index and hierarchical
clustering. A two-sample independent student t-test was used to assess differential expression.
Multiple testing was corrected using permutation-based false discovery rate (FDR) with the
following parameters, with significance set at less than 0.05.

204 Western Blotting

To further characterize and immune-phenotype, we performed western blots on placental 205 206 homogenates and STB-EV pellets. The relevant primary antibodies were used to probe all STB-EVs (as discussed in the main article). An equal amount of protein (20 micrograms) was mixed 207 208 with 4 X Laemmli buffer ((180 mM Tris-Cl (pH 6.8), 6% SDS, 30% glycerol, 0.3% 2-209 mercaptoethanol, and 0.0015% bromophenol blue, BioRad)). After heating the sample mix for 210 ten minutes at 70°C, an equal volume of the sample mix was loaded. Electrophoresis was 211 performed at 150 V for 1.5 hours in a Novex minicell tank (Invitrogen, UK) filled with NuPAGETM MOPS SDS running buffer under reducing (for PLAP, Cytochrome C, ALIX, SR-212 BI, Filamin B, PAPP-A2, Collagen 17 A1) and non-reducing (for CD 63) conditions on 213 214 NuPAGE TM 4-12% Bis-Tris Gel 1.0 mm x 10 well gels (Invitrogen by Thermo Fisher Scientific) (Novex by Life Technologies). As a protein size marker, Precision plus proteinTM 215 216 dual color standards (Bio-Rad Laboratories Ltd, Hertfordshire, UK) were used. Following protein separation, the proteins were transferred to a polyvinylidene difluoride (PVDF) 217 membrane (Bio-Rad). 218

In a Novex semi-dry transfer apparatus, the PVDF membrane and gel were sandwichedbetween four filter paper sheets pre-soaked in anode one buffer solution (300 mM Tris, 10%)

221 methanol pH 10.4) and two filter paper sheets pre-saturated with anode two buffer solution (25 222 mM Tris, 20% methanol pH 10.4) at the bottom and three filter paper sheets pre-soaked in 223 cathode buffer solution (25 mM Tris, 40 mM (Life Technologies, UK). For 45 minutes, the 224 transfer was run at 25 V. The membranes were blocked for one hour with 5% Blotto 225 (2BScientific) in 0.1% TBST (Tris-buffered saline (20 mM Tris, 137 mM NaCl, pH 7.6) and 226 1% Tween-20, Sigma), then incubated overnight with the appropriate antibody.

227 Antibodies used were SR-BI (ab52629 [0.35 µg/µl] 1:1000 dilution, monoclonal Rabbit, 228 Abcam), Filamin B (GTX387 [1.64 µg/µl] 1: 1000 dilution, monoclonal mouse, Insight 229 Biotechnology), PAPP-A2 (ab59100 [1 µg/µl] 1: 2000 dilution polyclonal Rabbit, Abcam), 230 Collagen 17 A1(ab28440 [1 µg/µl] 1: 2000 dilution polyclonal Rabbit, Abcam), and for 231 characterization, placental alkaline phosphatase (PLAP [1.667 µg/µl] at 1:1000 dilution in house antibody), CD 63 ([200 µg/µl]] at 1:1000 dilution, Sc-59286, Santa Cruz 232 233 Biotechnology), Alix ([200µg/µl]] at 1:1000 dilution, Sc-53538, Santa Cruz Biotechnology), 234 and Cytochrome C ([200 µg/µl]] at 1:1000 dilution, Sc-13156, Santa Cruz Biotechnology) as 235 recommended by the international society for extracellular Vesicles (ISEV).

236 After an overnight incubation and three five-minute TBST washes, the membranes were incubated for an hour at room temperature with the corresponding secondary antibody, anti-237 238 mouse (P044701-2) or anti-rabbit (P044801-2) polyclonal goat immunoglobulins/ horseradish 239 peroxidase (HRP) (1: 2000 dilution, Dako UK Ltd, Cambridgeshire UK) and rinsed three times in TBST. The membranes were developed using a gel documentation system (G-Box, Syngene, 240 Cambridge UK) running GeneSys (version 1.5.0.0, Syngene) and a chemiluminescence film 241 242 (Amersham HyperfilmTM ECL (enhanced chemiluminescence; GE Healthcare Limited, Buckinghamshire UK) to obtain the band intensity for each lane. The fold change (FC) between 243 244 normal and preeclampsia samples was calculated by normalizing the comparative expression

analysis to the total protein loaded (using Amido Black stain) 17,18. The normalized
densitometric values were statistically tested using a one-tailed Student t-test, with significance
set at less than 0.05. Tables 1 and 2 show the reagents and antibodies used in western blot
analysis, respectively. Details of western blot for STB-EV characterization and proteomic
validation experiments can be seen in the supplemental material.

250 This study utilized 12 samples for initial discovery and 12 for targeted western blot validation

251

252 **Results**

253 Patient demographics and clinical characteristics

254 PE mothers (Table 1), as expected, had a significantly higher average systolic (178.83 mmHg,

255 P < 0.001) and diastolic (109.17 mmHg, P < 0.001) blood pressure compared to normal

pregnant mothers average systolic (129.50 mmHg) and diastolic (67.00 mmHg). PE women

- are also significantly more likely to deliver prematurely (PE = 32.00 weeks gestation NP =
- 258 39.17 weeks gestation, P < 0.001) and have proteinuria (PE = 2.58 pluses on urine dipstick NP

259 = 0 pluses on urine dipstick, P < 0.001) compared to normal pregnancy

Finally, PE babies significantly weighed less than normal babies (PE = 1515.83g NP = 3912.50

261 g, P < 0.001). Surprisingly, we found no significant difference in body mass index, the gender262 of the child, and maternal age.

- 263
- 264
- 265
- 266
- 267
- 268

Page | 12

Characteristics	Sub-Classification	Normal Pregnancy	Preeclampsia	P Value
Sample size		6	6	
Maternal age years (m	ean (SD))	34.5 ± 5.39	36.33 ± 4.13	0.524
Systolic blood pressur	e mmHg (mean (SD))	129.5 ± 4.93	178.83 ± 12.56	<0.001
Diastolic blood pressu	re mmHg (mean (SD))	67 ± 6.2	109.17 ± 9.85	<0.001
Body mass index kg/n	n-2 (mean (SD))	29.92 ± 9.1	31.25 ± 11.12	0.825
Proteinuria plus(es) (n	nean (SD))	0	2.58 ± 1.2	<0.001
Gestational age at diag	gnosis in weeks (mean (SD))	NA	30.5 ± 3.50	0.001
Gestational age at deli	very in weeks (mean (SD))	39.17 ± 0.98	32 ± 3.52	0.001
Birth weight grams (ra	ange)	3912.5 ± 730.4	1515.83 ± 600.57	<0.001
Intrauterine growth res	striction (IUGR) = Yes (%)	0(0)	6(100)	0.004
Male new-born sex (%	5)	2(33.3)	2(33.3)	1.000

269	Table 1.	General	descriptive	statistics c	of sam	ple p	opulation
-----	----------	---------	-------------	--------------	--------	-------	-----------

270

271 Characterization of syncytiotrophoblast membrane extracellular vesicles (STB-EVs)

272 Flow cytometry (Figure 1) was showed that many detected events ($83-85 \pm 8.0-8.3\%$) were negative for CD 235a (Red blood cells), CD41 (platelets) and HLA-I and II (white blood cells) 273 (Figure 1B) while $92 \pm 0.9\%$ (Figure 1D and 1G) of detected events were PLAP⁺ extracellular 274 275 vesicles (BODIPY FL N-(2-aminoethyl)-maleimide (bioM) and placental alkaline phosphatase 276 (PLAP) double-positive). Detergent treatment, which could break down EVs, with NP-40 277 confirmed that majority (99%) of our samples were largely vesicular since only $0.1 \pm 0.12\%$ 278 of BODIPY FL N-(2-aminoethyl)-maleimide and PLAP double-positive events were detected 279 (a reduction of 99%) (Figure 1E and 1H).

280 Transmission electron microscopy on 10K STB-EV pellets (Figure 2A and 2B) and 150K STB-

EVs (Figure 2C and 2D) in our sample preparation showed the typical cup-shaped morphology 281

282 of extracellular vesicles on transmission electron microscopy (TEM) within the appropriate

283 size range. Western blot confirmed they express the classic syncytiotrophoblast membrane

284 marker, placenta alkaline phosphatase (PLAP), the extracellular vesicle markers ALIX and CD 63. In addition, they lacked the negative EV marker cytochrome C (Figure 3A). Nanoparticle 285 tracking analysis (NTA) confirmed the homogeneity of the 150K STB-EV pellets (small STB-286 287 EVs) (Figure 3B) with a modal size of (205.8 ± 67.7) nm and the heterogeneity of the 10K STB-EV pellets (medium/large STB-EVs) (Figure 3C) with a size range of (479.4 ± 145.6) 288 289 nm.

290



293 Figure 1. Flow analysis of medium/large STB-EVs in the 10K STB-EV pellet. Apogee beads mix were used to set the flow machine's light scatter resolution to 0.59-1.3 µm and 0.24-1.3 294 295 µm silica beads(A). Figure B shows the application of SSC and FSC PMTVs as determined by apogee beads mix for the analysis of m/ISTB-EVs in the 10K pellet. An investigation gate was 296 created to include only medium/large EVs negative for non-placental markers (C & F). 297 298 Extracellular vesicles from the investigation gate were further analyzed for staining by bioM and expression of PLAP (D & G). Figure E and H shows that the bioM⁺ PLAP⁺ EVs were 299

- sensitive to detergent treatment. The percent of B-Maleimide⁺ PLAP⁺ from the 0.59-1.3 µm 300
- 301 gate is consistent under both SSC conditions.



302

- 304 Figure 2. Results of STB-EV characterization. Figure A,B,C and D displays representative
- transmission electron microscopy (TEM) images with wide view (A and C), medium/large 305
- STB-EVs (B), and Small STB-EVs (D). 306



308	Figure 3. Results of STB-EV characterization. The western blot characterization of S STB-
309	EVs and mISTB-EVs (A). 10K refers to mISTB-EVs and 150K refers to s STB-EVs. CYT C
310	refers to cytochrome c. Figure 2A and 2B show the NTA results of m/ISTB-EVs (B) and sSTB-
311	EVs (C).

312

313

314 Differentially carried proteins (DCPs) in Placenta homogenate, Medium/Large STB-EVs
315 and Small STB-EVs in Preeclampsia versus normal pregnancies.

316 In total, using mass spectrometry, there were fifteen (15) proteins in the placenta, three hundred

and four (304) in m/ISTB-EVs, and seventy-three (73) in sSTB-EVs were differentially

318 expressed between preeclampsia (PE) and normal pregnancy (NP).

319 In the placenta (Table 2), isoform HMG-R of High mobility group protein (HMGA1),

320 Fibrinogen-like protein 1(FGL1), isoform 1 of Kinesin-like protein (KIF2A), Ig kappa chain C

321 *region (IGKC)* were the most abundant proteins based on fold change. Concomitantly, *serum*

322 paraoxonase/arylesterase 1 (PON1) and alpha-1B-glycoprotein (AIBG) were the least
323 abundant proteins.

324 For m/ISTB-EVs (Table 2), the most differentially abundant proteins were the *collagen alpha-*

325 1(XVII) chain (COL17A1), isoform 2 of Filamin-B (FLNB), tumor necrosis factor-alpha-

326 induced protein 2 (Fragment) (TNFAIP2) based on fold change. In contrast, the least

327 differentially abundant proteins were *sodium-dependent phosphate transporter 1 (SLC20A1)*,

328 methylthioribose-1-phosphate isomerase (Fragment) (MRI1), prostatic acid phosphatase

329 (*Fragment*) (*ACPP*) based on fold change.

330 Finally, the sSTB-EVs (Table 2) had solute carrier family 2, facilitated glucose transporter

331 member (SLC2A11), v-type proton ATPase 16 KDa proteolipid subunit (ATP6V0C),

332 pappalysin 2 (PAPP-A2) as the most differentially abundant by fold change while sodium-

dependent phosphate transporter 1 (SLC20A1) and isoform 2 of ADP-ribosylation factor
GTPase-activating protein (ARFGAP3) were the least differentially abundant. There were 25
differentially carried proteins (DCPs) including *filamin B* (*FLNB*), *ERO1-like protein alpha*(*ERO1A*), endoglin (*EGLN*), pappalysin-2 (PAPP-A2), siglec6 (SIGL6) shared between
m/ISTB-EVS and sSTB-EVs and only one protein, *isoform 1 of kinesin-like protein* (*KIF2A*)
shared between the placenta and the m/1 STB-EVs. Only one protein *chloride intracellular channel protein 3* (*CLIC3*), was found in all three sample sub-types (Table 3)

340

- **Table 2**: Top ten differentially expressed Proteins between normal and preeclampsia placentas
- 342 (bold font), medium/large STB-EVs (normal font), small STB-EVs(italics)

Protein	Symbol	LFC	Adjusted P.
			Value
Placenta			
Isoform HMG-R of High mobility group protein	HMGA1	3.14	0.03
HMG-I/HMG-Y			
Fibrinogen-like protein 1	FGL1	2.49	0.04
Isoform 1 of Kinesin-like protein KIF2A	KIF2A	1.47	0.02
Chloride intracellular channel protein 3	CLIC3	1.09	0.05
Mesencephalic astrocyte-derived neurotrophic factor	MANF	1.02	0.03
Ig kappa chain V-I region AG	KV101	-1.02	0.05
Haloacid dehalogenase-like hydrolase domain-	K7EJQ8	-1.23	0.05
containing protein 2 (Fragment)			
Ig kappa chain C region	IGKC	-1.27	0.05
Alpha-1B-glycoprotein	A1BG	-1.34	0.05
Serum paraoxonase/arylesterase 1	PON1	-2.18	<0.01
Medium/Large STB-EVs			

Page | 19

Collagen alpha-1(XVII) chain	COL17A1	4.79	<0.01
Isoform 2 of Filamin B	FLNB	3.09	<0.01
Tumor necrosis factor apha-inducible protein	TNFAIP2	3.03	<0.01
Minor histocompatibility antigen	HMHA1	1.59	0.03
Bridging integrator 2	BIN2	2.33	0.02
Sodium/potassium-transporting ATPase subunit beta-1	ATP1B	1.99	0.02
ERO-1 like protein alpha	ERO1L	1.97	<0.01
Endoglin	ENG	1.82	<0.01
Methylthioribose-1-phosphate isomerase (Fragment)	MRI1	-1.96	0.04
Sodium-dependent phosphate transporter 1	S20A1/SLC17A1	-5.24	0.04
Small STB-EVs			
Solute carrier family 2, facilitated glucose transporter	SLC2A11	8.91	0.01
member 11			
V-type proton ATPase 16 kDa proteolipid subunit	VATL	7.25	0.02
Pappalysin-2	PAPP2	3.76	0.02
ERO1-like protein alpha	ERO1A	3.29	0.02
Isoform 2 of Creatine kinase U-type, mitochondrial	KCRU	3.20	0.02
SCARB1 protein	B7ZKQ9	2.95	0.05
Isoform 2 of Filamin-B	FLNB	2.92	0.02
Solute carrier organic anion transporter family member	SO2A1	2.86	0.02
2A1			
Isoform 2 of Oligaccharyltransferase complex subunit TC	OSTC	2.82	0.02
SCY1-like protein 2	SCYL2	2.71	0.02
Sodium-dependent phosphate transporter 1	S20A1	-2.93	0.01
	1	1	۱

Table 3. List of overlapping differentially carried proteins in the placenta, medium/large STB-349

EVs and small STB-EVs 350

Sample types	Differentially expressed proteins (DEPs)
m/ISTB-EVs and Placenta	Kinesin-like protein
m/ISTB-EVs, sSTB-EVs and Placenta	Chloride intracellular channel protein 3
m/lSTB-EVs and sSTB-EVs	Filamin B
	Endoplasmic Reticulum Oxidoreductase Alpha
	X-linked retinitis pigmentosa GTPase regulator
	interacting protein 1
	Protein NDRG1
	Collagen alpha 1(XVII) chain
	Monocyte differentiation antigen CD14
	Trophoblast glycoprotein
	Heat shock-related 70 kDa protein 2
	Endoglin
	Hippocalcin-like protein 1
	SCARB1 protein
	Importin subunit alpha 7
	Protein BCAP
	Endothelial protein C receptor
	Caveolin
	Pappalysin-2
	Phosphatidylinositol 3-kinase regulatory subunit
	alpha
	Keratin, type I cytoskeletal 19
	Siglec6
	Protein disulfide-isomerase

Amine oxidase [flavin-containing] A
Copine-3
Dolichyl-diphosphooligosaccharide
Sodium-dependent phosphate transporter 1
Annexin A4

352

353

354 Validation of select proteins in the placenta homogenate, medium/Large STB-EVs, and small STB-EVs 355

356 We combined all the DCPs identified from the placenta, m/ISTB-EVs, and sSTB-EVs and

selected proteins to validate based on fold change and our placenta specificity or enrichment 357

358 as previously described above in the methods section. These were pappalysin A2 (PAPP-A2),

359 collagen 17A1 (COL17A1), filamin B, and scavenger receptor class B type I (SR-BI/SCARB1).

360 Validation was performed by western blot on all sample sub-types.

In the placenta (Figure 4A and 4D), *PAPP-A2* (FC =6.39, P Value = 0.0001) and *SR-BI* (FC = 361 1.72, P Value = 0.04) were all differentially abundant in PE. *Filamin B* (FC = 2.59, P Value = 362 0.12) was differentially abundant in PE but not significant while COL17A1 was undetectable. 363 364 In medium/large STB-EVs (Figure 4B and 4E), pappalysin A2 (FC =5.09, P Value = 0.004), collagen 17A1 (FC =71.21, P Value = 0.002), filamin B (FC =7.60, P Value = 0.014) and 365 scavenger receptor class B type I (FC = 2.28, P Value = 0.018) were all significantly 366 differentially abundant in PE compared to normal. In sSTB-EVs (Figure 4C and 4F), only 367 368 *filamin B* (FC =7.73, P Value = 0.003) and *SR-BI/SCARB1* (FC =1.60, P Value = 0.002) were significantly differentially abundant while COL17A1(FC =12.79, P Value = 0.07) and PAPP-369 370 A2 (FC = 1.48, P Value = 0.11) were differentially abundant but not significantly so.

Page | 22





Figure 4. Figure showing the results of western blot and densitometric verification of PAPP-373 374 A2, COL17A1, FLNB and SR-BI in the placenta (A and D) m/ISTB-EVs (B and E) and sSTB-EVs (C and F). Collagen 17A1 did not show up in the placenta homogenate. * means < 0.05, 375 ** means < 0.01, *** means < 0.001, **** means less than 0.001 and ns means non-significant. 376 377

Functional enrichment of differentially carried proteins (DCPs) in preeclampsia (PE) 378

379 We performed a functional enrichment analysis on the list of differentially carried proteins in placenta tissue, medium/large STB-EVs, and small STB-EVs to help better understand their 380 role in preeclampsia (PE). The three sample sub-types did not have overlapping gene ontology 381 terms or KEGG pathways. The top biological processes overrepresented in the placenta (Table 382 383 3A) were processes that involve *neurotransmitter secretion and transport*. In comparison, the 384 enriched biological processes in the m/ISTB-EVs (supplemental table 3) involved responses to 385 hypoxia. Finally, posttranslational protein modification processes were enriched among small 386 STB-EVs (supplemental table 3). Neurotrophin signaling pathway, spinocerebellar ataxia,

Page | **23**

and protein processing pathway were among the over enriched KEGG pathways in the
placenta, m/ISTB-EVs and sSTB-EVs respectively (Supplemental table 4).

- 389
- 390 Discussion

391 Principal findings

In our analysis, PE and NP have different placenta and STB-EV proteomes. Four STB-EV biomarkers—filamin B, collagen 17A1, pappalysin-A2, and scavenger Receptor Class B Type 1—were verified for differential abundance. In silico investigation revealed molecular pathways such abnormal protein metabolism that may contribute to PE's clinical and pathological symptoms and inform future research.

397 Results in the context of what is known.

Our analysis found chloride intracellular channel 3 (CLIC3) to be the only protein differentially abundant among all sample types. CLIC3 is expressed in the placenta throughout pregnancy(Money et al., 2007) and is abundant in PE placentas compared to NP, a finding corroborated by our results. However, it has not previously been described in terms of STB-EVs. CLIC3 also recycles activated integrins back to the plasma membrane and facilitates cell migration and invasion(Dozynkiewicz et al., 2012) a process that has been identified as abnormal in PE(KHONG et al., 1986).

We found *COL17A1* to be more abundant in PE m/ISTB-EVs but not detectable in the placenta
in both normal and PE. Although collagen 17 has not been described in preeclampsia, a protein
of the same family, collagen 1 is deposited in higher amounts in the PE placenta and can induce
preeclampsia-like symptoms by suppressing the proliferation and invasion of trophoblasts.
This suppression was reversible by treating with ERK and B-catenin agonists(Feng et al.,
2021). Likewise, *PAPP-A2* was significantly more abundant in the PE placenta and m/ISTBEVs. *PAPP-A2* cleaves insulin-like growth factor binding protein (IGFBP-5 and, to a lesser

Page | 24

412 extent, IGFBP-3). PAPP-A2's mRNA and protein are differentially expressed in the placenta
413 and maternal serum in PE patients(Whitehead et al., 2013).

Filamin B was significantly more abundant in PE m/ISTB-EVs and sSTB-EVs compared to 414 415 NP. Filamin B participates in cellular structural mechanics and signal transduction by 416 interacting with ion channels, signaling molecules, transmembrane proteins, and transcription factors(Zhou et al., 2010). It also suppresses tumor growth and metastasis(Iguchi et al., 2015). 417 418 Interestingly, in contrast to our study wei et al described Filamin B as being up regulated in the placenta (Wei et al., 2019). Wei et al used glyceraldehyde 3-phosphate dehydrogenase 419 420 (GAPDH) as an internal reference while we used total protein normalization to Amido black 421 to quantify and compare protein expression. GAPDH is an unreliable internal reference protein, particularly in preeclampsia(Lanoix et al., 2012) and this may explain these discordant 422 423 findings. In addition, in our proteomics data, we found GAPDH to be among the most 424 differentially expressed (upregulated) proteins.

Likewise, we identified scavenger receptor class B, type 1 (SCARB1/SR-BI) to be significantly increased in PE placenta, m/l and sSTB-EVs. SCARB1/SR-BI, is most abundant in the adrenal glands, placenta, liver, and brain(Ganesan et al., 2016; Shen et al., 2016). SR-BI facilitates the uptake of cholesteryl esters from high-density lipoproteins and lipid-soluble vitamin and transthyretin-bound thyroid hormone by placental trophoblast cells(Landers et al., 2018).

In terms of potential mechanisms of preeclampsia, we found no overlap in the biological processes and KEGG pathways among the three sample sub-type. In the placenta, gene ontology biological processes (GO: BP) involved in *neurotransmitter secretion and transport* were overrepresented while *platelet activation*, *MAPK* and *Rap 1 signaling* pathways were among the detected KEGG pathways. In m/ISTB-EVs, *protein modification process*, and *decreased oxygen level responses* were among the perturbed GO: BP terms. *Alzheimer's* and *prion disease* were among the identified KEGG pathways. In sSTB-EVs, *post-translational*

Page | 25

437 *modification processes* and *endoplasmic reticulum protein processing* were the principal GO:
438 BP terms and KEGG pathways.

Recent research has shown that ischemic hypoxia and the release of proinflammatory cytokines 439 440 in PE can cause protein misfolding and initiate endoplasmic reticulum (ER) stress due to 441 hypoxia-reoxygenation damage to the endoplasmic reticulum(Gathiram & Moodley, 2016). PE can also cause posttranslational modifications to proteins, such as changing the isoelectric 442 443 point, which results in different S-nitrosylation outcomes in placental proteins(Zhang et al., 2011). It is thought that the accumulation of these aggregates of unfolded protein response 444 445 (UPR) or misfolded proteins contributes to the pathophysiology of PE(Gathiram & Moodley, 2016). Other processes and KEGG pathways have been previously described in preeclampsia, 446 447 while others found in our study are new and may warrant further research(Lee et al., 2020; 448 Wan Shumei, Peng Ping, Qiao Lin, 2019).

449 Ideas and Speculation

450 STB-EVs are liquid biomarkers with real-time information from the damaged placenta in PE
451 due to their placenta-specificity. It would be interesting to test maternal plasma or serum
452 samples for the four STB-EV indicators reported in our study.

It is unclear which comes first: misfolded proteins depositing in trophoblasts and preventing normal invasion, causing ischemia and endoplasmic reticulum stress, which leads to defects in trophoblast invasion, oxidative stress, and endothelial cell dysfunction, or the trophoblast invasion defects, oxidative stress, and endothelial cell dysfunction, or the misfolded proteins because of faulty invasion and oxidative stress. Further studies exploring these PE pathogenic processes would be intriguing.

459

460

medRxiv preprint doi: https://doi.org/10.1101/2023.06.03.23290935; this version posted November 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

462 Strengths and limitations

463 Our study explored the difference in the proteome between PE and NP by analyzing the 464 placenta and its extracellular vesicles. This study is one of the few to do so using extracellular 465 vesicles obtained by a physiologic technique, the *ex-vivo* dual lobe placenta perfusion. 466 However, the control population used for this study was not gestationally age-matched because 467 it is impossible to obtain the ideal control for early onset PE patients. Also, our sample size 468 was small (n of 12).

469 Conclusion

Our study may have found novel STB-EV-bound protein indicators that are significantly more
abundant in PE than normal. Since STB-EVs are present in the circulation from early
pregnancy to term and are released more in PE, these STB-EV carried proteins may help with
earlier diagnosis and mechanistic insights.

474 Acknowledgments

We acknowledge the support of the National Institute of Health Research Clinical Research
Network for assistance in patient recruitment and Fenella Roseman and Lotoyah Carty,
research midwives who kindly recruited the patients for this study. We acknowledge the
patients who kindly consented to this research study.

479 **Competing interests:**

480 The authors declare no competing interests.

481

482

483

485 References

486	ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. (2019).
487	Obstetrics and Gynecology. https://doi.org/10.1097/AOG.0000000000003018
488	Awoyemi, T., Motta-Mejia, C., Zhang, W., Kouser, L., White, K., Kandzija, N., Alhamlan, F.
489	S., Cribbs, A. P., Tannetta, D., Mazey, E., Redman, C., Kishore, U., & Vatish, M.
490	(2021). Syncytiotrophoblast Extracellular Vesicles From Late-Onset Preeclampsia
491	Placentae Suppress Pro-Inflammatory Immune Response in THP-1 Macrophages.
492	Frontiers in Immunology, 12. https://doi.org/10.3389/FIMMU.2021.676056
493	Billieux, M. H., Petignat, P., Fior, A., Mhawech, P., Blouin, J. L., Dahoun, S., & Vassilakos,
494	P. (2004). Pre-eclampsia and peripartum cardiomyopathy in molar pregnancy: clinical
495	implication for maternally imprinted genes. Ultrasound in Obstetrics & Gynecology:
496	The Official Journal of the International Society of Ultrasound in Obstetrics and
497	<i>Gynecology</i> , 23(4), 398–401. https://doi.org/10.1002/UOG.1015
498	Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S.,
499	Hall, D. R., Warren, C. E., Adovi, G., & Ishaku, S. (2018). Hypertensive disorders of
500	pregnancy: ISSHP classification, diagnosis, and management recommendations for
501	international practice. In <i>Hypertension</i>
502	https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
503	Dozvnkiewicz, M. A., Jamieson, N. B., MacPherson, I., Grindlay, J., vandenBerghe, P. V. E.,
504	vonThun, A., Morton, J. P., Gourley, C., Timpson, P., Nixon, C., McKay, C. J., Carter,
505	R., Strachan, D., Anderson, K., Sansom, O. J., Caswell, P. T., & Norman, J. C. (2012).
506	Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late
507	Endosomes/Lysosomes and Drive Cancer Progression Developmental Cell 22(1) 131
508	https://doi.org/10.1016/I.DEVCEL.2011.11.008
509	Dragovic R A. Collett G P. Hole P. Ferguson D J P. Redman C. W. Sargent I L. &
510	Tannetta, D. S. (2015a). Isolation of syncytiotrophoblast microvesicles and exosomes
511	and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle
512	Tracking Analysis, <i>Methods (San Diego, Calif.)</i> , 87, 64–74.
513	https://doi.org/10.1016/J.YMETH.2015.03.028
514	Dragovic, R. A., Collett, G. P., Hole, P., Ferguson, D. J. P., Redman, C. W., Sargent, I. L., &
515	Tannetta, D. S. (2015b). Isolation of syncytiotrophoblast microvesicles and exosomes
516	and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle
517	Tracking Analysis, <i>Methods</i> , 87, 64–74, https://doi.org/10.1016/i.vmeth.2015.03.028
518	Feng, Y., Chen, X., Wang, H., Chen, X., Lan, Z., Li, P., Cao, Y., Liu, M., Ly, J., Chen, Y.,
519	Wang, Y., Sheng, C., Huang, Y., Zhong, M., Wang, Z., Yue, X., & Huang, L. (2021).
520	Collagen I Induces Preeclampsia-Like Symptoms by Suppressing Proliferation and
521	Invasion of Trophoblasts. Frontiers in Endocrinology, 12.
522	https://doi.org/10.3389/fendo.2021.664766
523	Ganesan, L. P., Mates, J. M., Cheplowitz, A. M., Avila, C. L., Zimmerer, J. M., Yao, Z.,
524	Maiseveu, A., Rajaram, M. V. S., Robinson, J. M., & Anderson, C. L. (2016). Scavenger
525	receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial
526	cells. <i>Scientific Reports</i> , 6. https://doi.org/10.1038/srep20646
527	Gathiram, P., & Moodley, J. (2016). Pre-eclampsia: its pathogenesis and pathophysiolgy.
528	Cardiovascular Journal of Africa, 27(2), 71–78, https://doi.org/10.5830/CVJA-2016-
529	009
530	Germain, S. J., Sacks, G. P., Sooranna, S. R., Soorana, S. R., Sargent, I. L., & Redman, C. W.
531	(2007). Systemic inflammatory priming in normal pregnancy and preeclampsia: the role
532	of circulating syncytiotrophoblast microparticles. <i>Journal of Immunology (Baltimore.</i>
533	<i>Md.</i> : 1950), 178(9), 5949–5956. https://doi.org/10.4049/JIMMUNOL.178.9.5949

534 535 536 537 538 539	 Goswamia, D., Tannetta, D. S., Magee, L. A., Fuchisawa, A., Redman, C. W. G., Sargent, I. L., & von Dadelszen, P. (2006). Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. <i>Placenta</i>, <i>27</i>(1), 56–61. https://doi.org/10.1016/J.PLACENTA.2004.11.007 Hailu, F. G., Yihunie, G. T., Essa, A. A., & Tsega, W. kindie. (2017). Advanced abdominal pregnancy with live fetus and severe preeclampsia case report. <i>BMC Pregnancy and</i>
540	Childhirth 17(1) https://doi.org/10.1186/\$12884-017-1437-V
540	Laughi V. Jahihara S. Llahida V. Taiima K. Mizutani T. Kawahata K. & Haga H.
541	(2015) Filomin P onbancos the investiveness of concer cells into 2D collegon metrices
542	<i>Coll Structure and Function</i> 40(2) https://doi.org/10.1247/oof.15001
545	Koorthikumar S. Gangoda I. Liom M. Fonsaka P. Atukorala I. Ozoitti C. Machlar A.
544	Adda C. G. Ang C. S. & Mathiyanan S. (2015). Protogranomic analysis rayaals
545	Adua, C. O., Alig, C. S., & Matin Valian, S. (2013). Floteogenomic analysis reveals
	https://doi.org/10.19622/ONCOTADCET 2801
547 E10	1000000000000000000000000000000000000
540 E40	motornal vacaular regenerate to placentation in programming complicated by pro-colomories
549	and by small for asstational assistants. <i>BIOC: An Intermetional Journal of Obstations</i>
	L Currange lague 02(10) https://doi.org/10.1111/j.1471.0529.1096.th07920.v
221	a Gyndecology, 95(10). https://doi.org/10.1111/j.14/1-0528.1980.00/850.x
	(2018) Transthurstin untake in placental calls is regulated by the high density
	(2016). Transmyretin uptake in placental cens is regulated by the high-defisity
	Endoaringloom 474 https://doi.org/10.1016/i.mag.2018.02.014
555	Lanciv D. St Diarra I. Lancesco A. A. Vieu M. Lafond I. & Vaillancourt C. (2012)
550	Lanoix, D., St-Fiene, J., Lacasse, A. A., Viau, M., Latonu, J., & Valuation, C. (2012).
557	benchmark <i>Placenta</i> 33(3) https://doi.org/10.1016/j.placenta.2011.12.008
550	Lee A Chow I Skeith I Nicholas I A Doop M C Doole A W & Aghani E O
560	(2020) Platalet Membrane Processful ation in Preeclampsia <i>Blood</i> 136(Supplement 1)
561	https://doi.org/10.1182/blood_2020_137213
562	Lisonkova S & Josenh K S (2013) Incidence of preeclampsia: risk factors and outcomes
563	associated with early-versus late-onset disease American Journal of Obstetrics and
564	Gynecology 209(6) 544 e1-544 e12 https://doi org/10.1016/I A IOG 2013.08.019
565	Minciacchi V R Spinelli C Reis-Sobreiro M Cavallini L You S Zandian M Li X
566	Mishra R. Chiarugi P. Adam R. M. Posadas F. M. Viglietto G. Freeman M. R.
567	Cocucci, E., Bhowmick, N. A., & Di Vizio, D. (2017), MYC Mediates Large
568	Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. <i>Cancer Research.</i>
569	77(9), 2306–2317. https://doi.org/10.1158/0008-5472.CAN-16-2942
570	Money, T. T., King, R. G., Wong, M. H., Stevenson, J. L., Kalionis, B., Erwich, J. J. H. M.,
571	Huisman, M. A., Timmer, A., Hiden, U., Desoye, G., & Gude, N. M. (2007). Expression
572	and Cellular Localisation of Chloride Intracellular Channel 3 in Human Placenta and
573	Fetal Membranes. <i>Placenta</i> , 28(5–6), 429–436.
574	https://doi.org/10.1016/J.PLACENTA.2006.08.002
575	Nakahara, A., Nair, S., Ormazabal, V., Elfeky, O., Garvey, C. E., Longo, S., & Salomon, C.
576	(2020). Circulating Placental Extracellular Vesicles and Their Potential Roles During
577	Pregnancy. Ochsner Journal, 20(4), 439–445. https://doi.org/10.31486/toj.20.0049
578	Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and
579	friends. Journal of Cell Biology, 200(4), 373–383.
580	https://doi.org/10.1083/JCB.201211138
581	Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., & Vilo, J. (2019).
582	G:Profiler: A web server for functional enrichment analysis and conversions of gene
583	lists (2019 update). Nucleic Acids Research, 47(W1). https://doi.org/10.1093/nar/gkz369

Page | 29

584 585 586 587 588 589 590 591 592 593 594 595	 Redman, C. (2014). Pre-eclampsia: A complex and variable disease. <i>Pregnancy</i> <i>Hypertension</i>, 4(3), 241–242. https://doi.org/10.1016/J.PREGHY.2014.04.009 Redman, C. W. G., Staff, A. C., & Roberts, J. M. (2022). Syncytiotrophoblast stress in preeclampsia: the convergence point for multiple pathways. <i>American Journal of</i> <i>Obstetrics and Gynecology</i>, 226(2S), S907–S927. https://doi.org/10.1016/J.AJOG.2020.09.047 Shen, W. J., Azhar, S., & Kraemer, F. B. (2016). ACTH regulation of adrenal SR-B1. In <i>Frontiers in Endocrinology</i> (Vol. 7, Issue MAY). https://doi.org/10.3389/fendo.2016.00042 Soto-Wright, V., Bernstein, M., Goldstein, D. P., & Berkowitz, R. S. (1995). The changing clinical presentation of complete molar pregnancy. <i>Obstetrics and Gynecology</i>, 86(5), 775–779. https://doi.org/10.1016/0029-7844(95)00268-V
596	Thadhani, R., Lemoine, E., Rana, S., Costantine, M. M., Calsavara, V. F., Boggess, K.,
597	Wylie, B. J., Simas, T. A. M., Louis, J. M., Espinoza, J., Gaw, S. L., Murtha, A.,
598	Wiegand, S., Gollin, Y., Singh, D., Silver, R. M., Durie, D. E., Panda, B., Norwitz, E.
599	R., Kilpatrick, S. (2022). Circulating Angiogenic Factor Levels in Hypertensive
600	Disorders of Pregnancy. NEJM Evidence, 1(12).
601	https://doi.org/10.1056/EVIDOA2200161
602	Tkach, M., Kowal, J., Zucchetti, A. E., Enserink, L., Jouve, M., Lankar, D., Saitakis, M.,
603	Martin-Jaular, L., & Théry, C. (2017). Qualitative differences in T-cell activation by
604	dendritic cell-derived extracellular vesicle subtypes. <i>The EMBO Journal</i> , <i>36</i> (20), 3012–
605	3028. https://doi.org/10.15252/EMBJ.201696003
606	Wan Shumei, Peng Ping, Qiao Lin, G. Y. (2019). Expression of miR-144, titin-Ab and
607	MAPK signal transduction pathway related proteins in pre-eclampsia patients.
608	INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,
609	I1(127), 11-20. www.ijcem.com/ISSN:1940-5901/IJCEM0098123
610	wei, J., Fu, Y., Mao, X., Jing, Y., Guo, J., & Ye, Y. (2019). Decreased Filamin b expression
611 612	Cinckelegia Deleka, 00(1), 20, 45, https://doi.org/10.5602/CD.2010.0006
01Z 612	Whitehead C. I. Walker S. P. Ve I. Mendis S. Kaitu'u Lino, T. I. Lappas M. & Tong
617	S (2013) Placental specific mPNA in the maternal circulation are globally dysregulated
615	in pregnancies complicated by fetal growth restriction. <i>Journal of Clinical</i>
616	Endocrinology and Metabolism 98(3) https://doi.org/10.1210/ic.2012-2468
617	Zabel R R Bär C Ji J Schultz R Hammer M Groten T Schleussner F Morales-
618	Prieto D M Markert II R & Favaro R R (2021) Enrichment and characterization
619	of extracellular vesicles from ex vivo one-sided human placenta perfusion American
620	Journal of Reproductive Immunology (New York NY \cdot 1989) 86(2)
620	https://doi.org/10.1111/AII.13377
622	Zeisler H Llurba E Chantraine E Vatish M Staff A C Sennström M Olovsson M
623	Brennecke S P Stepan H Allegranza D Dilba P Schoedl M Hund M &
624	Verlohren S. (2016) Predictive Value of the sFlt-1 PIGE Ratio in Women with
625	Suspected Preeclampsia. The New England Journal of Medicine, 374(1), 13–22.
626	https://doi.org/10.1056/NEJMOA1414838
627	Zhang, H. H., Wang, Y. P., & Chen, D. B. (2011). Analysis of nitroso-proteomes in
628	normotensive and severe preeclamptic human placentas. <i>Biology of Reproduction</i> , 84(5),
629	966–975. https://doi.org/10.1095/BIOLREPROD.110.090688
630	Zhou, A. X., Hartwig, J. H., & Akyürek, L. M. (2010). Filamins in cell signaling,
631	transcription and organ development. In Trends in Cell Biology (Vol. 20, Issue 2).
632	https://doi.org/10.1016/j.tcb.2009.12.001
633	

medRxiv preprint doi: https://doi.org/10.1101/2023.06.03.23290935; this version posted November 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Page | 30

634 Supplemental Material

- 635 Supplemental Methods
- 636 Supplemental table S1-4
- 637 Supplemental figure S1
- 638 List of differentially abundant proteins and functional enrichment analysis:
- 639 <u>https://data.mendeley.com/datasets/j2x4h9ddcj/draft?a=8ccd383c-c6e5-495d-b66b-</u>
- 640 <u>29c691608995</u>

675	
676	
677	
678	
679	
680	
681	
682	
683	
684	Supplemental data
684 685	Supplemental data
684 685 686	Supplemental data
684 685 686 687	Supplemental data
684 685 686 687 688	Supplemental data
684 685 686 687 688 689	Supplemental data
684 685 686 687 688 689 690	Supplemental data
684 685 686 687 688 689 690 691	Supplemental data

medRxiv preprint doi: https://doi.org/10.1101/2023.06.03.23290935; this version posted November 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Page | 32

693 Supplemental methods

694



Supplemental figure 1. Flow chart illustrating the steps involved in characterizing m/ISTBEVs and sSTB-EVs obtained via differential ultracentrifugation (10,000 and 150,000 g) of
maternal perfusate. Nanoparticle trafficking analysis, transmission electron microscopy, flow
cytometry, and western blot were used to characterize the pellets from both spins.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.03.23290935; this version posted November 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

700 Transmission electron microscopy

701 The Sir William Dunn School of Pathology was contracted to perform transmission electron 702 microscopy. STB-EV pellets were diluted with fPBS to produce STB-EV solutions with concentrations ranging from 0.1 to 0.3 g/l. For 2 minutes, ten microliter of the STB-EV pellet 703 704 solution was applied to freshly glowing discharged carbon formvar 300 mesh copper grids, 705 blotted with filter paper, stained with 2% uranyl acetate for 10 seconds, blotted, and air-dried. 706 The grid's STB-EV pellets are negatively stained to increase the contrast between the STB-EV 707 pellets and the background. The grids were imaged with a Gatan OneView CMOS camera on 708 an FEI Tecnai 12 TEM at 120 kV.

709 Nanoparticle tracking analysis.

The Nanosight NS500 (instrument equipped with a 405 nm laser [Malvern UK]), sCMOS 710 711 camera, and nanoparticle tracking analysis (NTA) software version 2.3, Build 0033 (Malvern UK)) system wased used for the analysis. Instrument performance was tested with silica 100 712 713 nm microspheres prior to sample analysis (Polysciences, Inc.). The samples were diluted in 714 fPBS to a concentration to 1/100,000 based on the starting concentration. The samples were 715 automatically injected into the sample chamber with a 1 ml syringe using the EV measurement 716 script: prime, delay of 5, capture of 60, and repeat of 4. Camera images of the analyzed samples were captured at a level of 12. (Camera shutter speed; 15 ms and Camera gain; 350). NTA 717 718 post-acquisition settings were optimized and maintained constant across samples. Each video 719 recording was analyzed to determine the size and concentration profile of STB-EV.

720

Page | 34

Western blotting

Supplemental table 1. Reagents used for western blot.

Buffers	Power of hydrogen (pH)	Constituents
4X Laemmli reducing buffer	6.8	9 parts 4 X Laemmli buffer
		1 part 2-beta-mercaptoethanol
4X Laemmli non-reducing buffer		4 X Laemmli buffer
Anode buffer 1	10.4	300 mM Tris base (36.34 g/L)
		100 % methanol (20 mL/L)
		980 ml of ddH ₂ O
Anode buffer 2	10.4	25 mM Tris base (3.0 g/L)
		100 % methanol (20 mL/L)
		980 ml of ddH ₂ O
Cathode buffer	9.4	25 mM Tris base (3.0 g/L)
		40 nM 6-aminocaproic acid (5.2 g/L)
		100 % methanol (20 mL/L)
		980 mL of dH2o
10 X TBS	8	NaCl (87.6g)
		Tris base (12.1g)
		700 ml of ddH ₂ O
TBST	8	10 X TBS (100 mL)
		0.1 % Tween-20 (1 mL)
		900 mL of ddH ₂ O
5% Milk TBST		5g of Blotto in 100 mL of TBST

Page | 35

Antibodies	Concentration	Dilution	Antigen	Specificity	Manufacturer
Anti-PLAP	1.6 µg/µl	1/1000	PLAP	STB-EV	In house antibody
(NDOG 2)	101				
Anti-CD63	200 ug/ul	1/1000	CD63	STB-EV	Santa Cruz
					Biotechnology
Anti-ALIX	200 µg/µl	1/1000	ALIX	S STB-EV	Cell Signalling
Anti-	200 µg/µ1	1/500	Cytochrome	Placenta	Santa Cruz
Cytochrome C	200 μ <u>β</u> /μι	1/500	C	homogenate	Biotechnology
A ref. CD DI	0.25	1/1000		N/A	Abaam
Anu-SK-BI	0.35 µg/µ1	1/1000	SK-BI	IN/A	Abcam
Anti-Filamin B	1.64 µg/µl	1/1000	Filamin B	N/A	Insight
					Biotechnology
Anti-PAPP-A2	1 μg/μl	1/2000	PAPP-A2	N/A	Abcam
Anti-Collagen	1 ug/ul	1/1000	Collagen 17	N/A	Abcam
17 A1		_,	Al		
Polyclonal goat-	-anti-mouse/rabbit	1/2000	Mouse and	N/A	Dako UK Ltd
immunoglobulin	HRP		Rabbit		
			Immunoglob		
			uling		
1			unns	1	1

731	Supplemental	table 2.	Antibodies	used for	western blot.
-----	--------------	----------	------------	----------	---------------

732

733 Bioinformatic analysis of proteomic data from placenta tissue, medium/large and small 734 **STB-EVs**

735 Persus (Max Planck Institute of Biochemistry) was used for the analysis, along with the 736 accompanying documentation and tutorials. To remove invalid data, we pre-processed the raw data by log transforming and filtering. Missing values were imputed at random from a normal 737 738 distribution using the following parameters: width = 0.3 and downshift = 1.8. To ensure 739 conformity to the normal distribution, the underlying distribution was visually inspected with 740 a histogram before and after missing data imputation. The data was then transformed further 741 by deducting each (transformed) value from the highest occurring protein expression value.

Principal component analysis (PCA), heatmaps, and Pearson correlation matrices were used to 742 743 further investigate the data. The data was analyzed using the correlation index and hierarchical 744 clustering. A two-sample independent student t-test was used to assess differential expression. 745 Multiple testing was corrected using permutation-based false discovery rate (FDR) with the 746 following parameters, with significance set at less than 0.05.

- Functional enrichment of differentially expressed proteins (DEPs) in preeclampsia (PE)
- Supplemental table 3: The top three functionally enriched gene ontologies are: biological
- process (GO: BP) Placenta (bold font), medium/large STB-EVs (normal font), and small STB-
- EVs (italics).

Biological Process (BP)	Adjusted P Values	No of Proteins in BP terms	No of DEP queried	No of DEP found in BP terms
Negative regulation of neurotransmitter secretion	0.02	2	14	2
Negative regulation of synaptic vesicle exocytosis	0.02	2	14	2
Negative regulation of	0.05	3	14	2
neurotransmitter transport				
Response to decreased oxygen	0.00	84	293	30
levels				
Cellular response to decreased	0.00	59	293	24
oxygen levels				
Cellular ketone metabolic process	0.00	65	293	26
Peptidyl-asparagine modification	0.02	10	73	5
Protein N-linked glycosylation via	0.02	10	73	5
asparagine				
Protein N-linked glycosylation	0.02	16	73	6

- Supplemental table 4: The top three functionally enriched KEGG Pathways in the placenta,
- medium/large STB-EVs, and small STB-EVs (only 1 KEGG). Placenta (bold font),
- medium/large STB-EVs (normal font), and small STB-EVs (italics)

KEGG Pathways (KP)	Adjusted P Values	No of Proteins in KP terms	No of DEP queried	No of DEP found in KP terms
Neurotrophin signalling pathway	0.00	13	14	3
Long-term potentiation	0.01	6	14	2
Renal cell carcinoma	0.02	11	14	2
Proteasome	0.00	35	293	17
Spinocerebellar ataxia	0.00	48	293	21
Alzheimer disease	0.01	94	293	29
Protein processing in endoplasmic reticulum	0.02	60	73	10

Major Resources Table

Antibodies

Target antigen	Vendor or Source	Catalog #	Working concentration	Dilution
PLAP	In house antibody		1.6 µg/µl	1/1000
CD63	Santa Cruz	sc-365604	200 µg/µl	1/1000
	Biotechnology			
ALIX	Cell Signalling	#2171	200 µg/µl	1/1000
Cytochrome C	Santa Cruz	sc-13560	200 µg/µl	1/500
	Biotechnology			
SR-BI	Santa Cruz	ab52629	0.35 µg/µl	1/1000
	Biotechnology			
Filamin B	Insight	GTX387	1.64 µg/µl	1/1000
	Biotechnology			
PAPP-A2	Abcam	ab59100	1 μg/μl	1/1000
Collagen 17A1	Abcam	Ab28440	1 μg/μl	1/2000
Mouse	Dako UK Ltd	P044701	1 μg/μl	1/2000
Immunoglobulins				
Rabbit	Dako UK Ltd	P044801	1 µg/µl	1/2000
Immunoglobulins				

Page | 38

Flow cytometry resources

Markers	Fluorochromes	Clone	CAT	Isotyp	Dilution
				e	/ Concentration
CD41	PE Vio770	REA386	130-105-562	REA	1 in 50 for dump channel
CD235	PE Vio770	RAE-175	130-100-258	REA	
HLA Class-I (ABC)	PE Vio770	REA230	130-101-460	REA	
HLA Class-II (DRDPDQ)	PE Vio770	RAE-332	130-104-828	REA	
REA control				REA	
CD41	Pacific blue	HIP8	303713	Mouse IgG1	1 in 100
CD235	Pacific blue	HI264	349107	Mouse IgG2a	1 in 100
HLA Class-I (ABC)	Pacific blue	W6/32	311417	Mouse IgG2a	1 in 100
PLAP	PE	Mouse mAb	N/A	IgG1	0.2mg/ml
IgG2a isotype control	Pacific blue	MOPC-173	981904	IgG2a	1 in 500
IgG1 isotype control	Pacific blue	MOPC-21	400131	IgG1	1 in 200
bioM	FITC	NA	NA	NA	0.5-1nM